Table 124.3Representative Regimens for AML

DoseRouteDays
Induction
Cytarabine +100-200 mg/m2Continuous IV infusion1–7 days
Daunorubicin or45mg/m2IV1–3
Idarubicin or12 mg/m2IV1–3
Mitoxantrone12 mg/m2IV1–3
Postremission
Cytarabine3 g/m2 q12hIV (over 3 hours)1, 3, 5 (6 doses)
Cytarabine1.5–2 g/m2q12hIV (over 1 hour)1–4 (8 doses)
1-6 (12 doses)
Cytarabine100 mg/m2Continuous IV infusion1–5

See text for details about number of courses and patient selection for different regimens.

From: Chapter 124, Acute Myeloid Leukemia in Adults

Cover of Holland-Frei Cancer Medicine
Holland-Frei Cancer Medicine. 5th edition.
Bast RC Jr, Kufe DW, Pollock RE, et al., editors.
Hamilton (ON): BC Decker; 2000.
© 2000, BC Decker Inc.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.